DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Progression of retinal nerve fibre layer damage in betaxolol- and timolol-treated glaucoma patients.

Author(s): Vainio-Jylha E, Vuori ML, Nummelin K

Affiliation(s): Department of Ophthalmology, Turku University Hospital, Finland.

Publication date & source: 2002-10, Acta Ophthalmol Scand., 80(5):495-500.

Publication type: Clinical Trial; Randomized Controlled Trial

PURPOSE: It has been suggested that there are differences between selective and non-selective beta-blocking agents in their ability to protect glaucomatous eyes. The purpose of this study was to follow glaucoma patients treated with either betaxolol 0.5% or timolol 0.25% ophthalmic solutions and to compare the rate and degree of progression in retinal nerve fibre layer (RNFL) defects between the groups. METHODS: A total of 64 patients were prospectively recruited in a double-masked study and randomly divided into two treatment groups. Retinal nerve fibre layer photographs were analysed. The incidence and total amount of progression in each group were recorded. The rate of impairment was demonstrated using Kaplan Meier survival curves. RESULTS: The analysis included 27 patients treated with betaxolol and 28 patients treated with timolol. Of these, 30% of betaxolol-treated patients and 46% of timolol-treated patients had RNFL damage progression (p = 0.20). The total amount or rate of progression did not differ significantly between the two groups. There was no significant difference in intraocular pressure (IOP) levels between the groups (p = 0.68) during follow-up. The degree of RNFL deterioration did not correlate to the amount of IOP reduction. CONCLUSION: The group treated with betaxolol 0.5% and the group treated with timolol 0.25% did not differ significantly in RNFL damage progression.

Page last updated: 2006-01-31

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017